Olopatadine, Ketotifen, Alcaftadine

Rapid-Acting Immunomodulators

Dual-action antihistamines combine competitive blockade of histamine receptors with intrinsic stabilization of mast cells, providing rapid improvement of pruritus and conjunctival edema in allergic conjunctivitis.

Mechanism

💊 Commercial Names

Opatanol, Patanol, Zaditen Ofta, Lastacaft, Ketotifeno Kern, Olopatadina Alcon.

🔬 Pharmacological Group

Selective antagonists of receptor H₁ histamine and mast cell membrane stabilizers. Pyridine and dibenzoxepin derivatives.

🧪 Standard Formulations

Olopatadine hydrochloride 0.1% and 0.2% (single-dose and multidose), ketotifen fumarate 0.025%, alcaftadine 0.25%.

Mechanism of Action

These dual-action agents modulate the immediate and late phases of the allergic cascade in the conjunctival tissue:

Selective Antagonism of Receptor H₁: They competitively bind to histamine receptor H₁ expressed in the endothelial cells of conjunctival vessels and in the nociceptors of free nerve endings. This instantly stops vasodilation, increased capillary permeability (chemosis) and intense conjunctival itching.
Mast Cell Stabilization: They directly inhibit the opening of voltage-gated calcium channels in the mast cell cell membrane, preventing the influx of extracellular calcium necessary for the polymerization of microtubules and the subsequent exocytosis of secretory granules that contain preformed allergic mediators (histamine, tryptase, chymase).
Inhibition of the Late Phase of the Allergic Reaction: They reduce chemotaxis and local activation of eosinophils and neutrophils, and stop the conjunctival release of proinflammatory cytokines such as ICAM-1, IL-4, IL-6 and IL-8, blocking the chronicity of the allergic process.

Pharmacokinetics

Quantitative Ocular and Systemic Pharmacokinetics

Parameter	Olopatadine 0.2%	Ketotifen 0.025%	Alcaftadine 0.25%
Onset of Relief	Immediate in 10 - 15 minutes.	Immediate in 15 minutes.	Immediate in 3 minutes (The fastest in his group).
Duration of Effect	Up to 12 - 24 hours (allows dosage of 1 dose per day).	Up to 12 hours of dural symptomatic relief.	Up to 24 hours of conjunctival allergic protection.
Clearance and Metabolism	Low systemic absorption; it is excreted mainly unchanged by the kidney.	Inactive secondary phase I hepatic metabolism.	Metabolism by demethylation to prolonged secondary active metabolite.
Half-life (t_1/2)	t_1/2 in plasma ≈ 3 - 4 hours.	t_1/2 plasma ≈ 12 hours.	t_1/2 plasma ≈ 30 minutes (metabolite: 2 hours).

Security

Contraindications

Absolute: Documented hypersensitivity to the active salt or any of the components of the eye drops.
Relative: Use of soft contact lenses during instillation (the preservative benzalkonium chloride is absorbed into the hydrogel of the lens, causing irreversible discoloration of the lens and inducing delayed corneal epitheliotoxicity; it should be advised to remove the lenses and wait at least 15-20 minutes before inserting them).

Adverse Effects (ADR)

Ocular Sites: Mild transient burning or stinging sensation post-dosage; dry eye due to slight secondary muscarinic blockade activity; superficial punctate keratitis; transient tearing and blurred vision.
Systemic: Mild tension headache, asthenia, dryness of the nasal mucosa and mild hyposmia. No or negligible central sedation compared to classic first-generation systemic antihistamines.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousNepafenac, Ketorolac, Bromfenac NextCiclosporin A, Lifitegrast

System: Ophthalmology
Group: Rapid-Acting Immunomodulators

Download Epistemis